CANCER DRUG DEVELOPMENT PIPELINE

Oncology Drug Pipeline & Cancer Clinical Trials

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline & Trials

Oncology Pipeline as of July 28, 2021

  • Discovery Projects
  • Phase 1
    16
  • Phase 2
    7
  • Phase 3
    8
  • Registration
    1
  • Total32
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (E.U.) Registration Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 kinase inhibitor
Go to clinical trial
ER+/HER2+ Metastatic Breast Cancer(PATINA) Phase 3 Product Enhancement Small Molecule
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Non-Muscle-Invasive Bladder Cancer (Biologic) Phase 3 New Molecular Entity Biologic
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer Phase 3 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Combo w/ Xtandi (enzalutamide) for DDR-deficient Metastatic Castration Sensitive Prostate Cancer
Project advanced
Phase 3 Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic High-Risk Castration Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor andMEK inhibitor and anti PD-1
BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma Phase 3 Product Enhancement Small Molecule
Braftovi (encorafinib) + Erbitux® (cetuximab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor and anti EGFR
Go to clinical trial
1st line BRAF-mutant Metastatic Colorectal Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/CMP-001 for Head and Neck Cancer (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) Phase 2 Product Enhancement Biologic
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor andMEK inhibitor
1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer Phase 2 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
Elranatamab
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
BCMA-CD3 Bispecific Antibody
Multiple Myeloma Triple-Class Refractory (Biologic) Phase 2 New Molecular Entity Biologic
ARV-471
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
ER-targeting PROTAC® protein degrader
ER+/HER2- Metastatic Breast Cancer
Project advanced
Phase 2 New Molecular Entity Small Molecule
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
EZH2 Inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 Inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-06939999
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
protein arginine methyltransferase 5 (PRMT5) Inhibitor
Solid Tumors Phase 1 New Molecular Entity Small Molecule
PF-06940434
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Integrin alpha-V/beta-8 Antagonist
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic
PF-06952229
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-07062119
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
GUCY2c CD3 Bispecific Antibody
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic
PF-07104091
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK2 Inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-07209960
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
interleukin 15 (IL15) Activator
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic
PF-07220060
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK4 Inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-07265807
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
AXL/MERTK Inhibitor
Solid Tumors Phase 1 New Molecular Entity Small Molecule
PF-07248144
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
KAT6A Epigenetic modifier
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-07284890
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
BRAF kinase Inhibitor
Melanoma Phase 1 New Molecular Entity Small Molecule
PF-07284892
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
SHP2 tyrosine phosphatase Inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
ARV-471
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
ER-targeting PROTAC® protein degrader
ER+/HER2- Metastatic Breast Cancer
Project advanced
Phase 1 Product Enhancement Small Molecule
Ibrance + ARV-471
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 4,6 kinase inhibitor + ER-targeting PROTAC® protein degrader
ER+/HER2- Metastatic Breast Cancer
Project advanced
Phase 1 Product Enhancement Small Molecule